{
    "id": "correct_subsidiary_00046_0",
    "rank": 39,
    "data": {
        "url": "https://www.gsk.com/en-gb/media/press-releases/",
        "read_more_link": "",
        "language": "en",
        "title": "Press releases",
        "top_image": "https://www.gsk.com/media/8584/ware_3_2022_prodassmb_28_hess.jpg?anchor=center&mode=crop&quality=90&width=600&height=315&rnd=133003836670000000",
        "meta_img": "https://www.gsk.com/media/8584/ware_3_2022_prodassmb_28_hess.jpg?anchor=center&mode=crop&quality=90&width=600&height=315&rnd=133003836670000000",
        "images": [
            "https://www.gsk.com/media/10847/gsk_tech_human_image_6k.jpg?mode=stretch&width=329&height=185&bgcolor=fff",
            "https://www.gsk.com/media/9354/trust_nicola_nav.jpg?mode=stretch&width=329&height=185&bgcolor=fff",
            "https://www.gsk.com/media/9932/vaccine-manufacturing-production-line-1.jpg?mode=stretch&width=329&height=185&bgcolor=fff",
            "https://www.gsk.com/media/8313/tony-16x9.jpg?mode=stretch&width=329&height=185&bgcolor=fff",
            "https://www.gsk.com/media/9347/web03-header-stvg_2_2022_port_5_hess_nav.jpg?mode=stretch&width=329&height=185&bgcolor=fff",
            "https://www.gsk.com/media/9295/navthumb_stvg_03_2022_port_32_eagle_orange-1.jpg?mode=stretch&width=329&height=185&bgcolor=fff",
            "https://www.gsk.com/media/9346/web16-header-stvg_2_2022_port_13_hess_nav.jpg?mode=stretch&width=329&height=185&bgcolor=fff",
            "https://www.gsk.com/media/9345/gsk_texture_fluid_03_a_cmyk_web-size_nav.jpg?mode=stretch&width=329&height=185&bgcolor=fff",
            "https://www.gsk.com/media/9351/ware_3_2022_prodassmb_28_hess_nav.jpeg?mode=stretch&width=329&height=185&bgcolor=fff",
            "https://www.gsk.com/media/9350/ware_3_2022_prodqc_14_hess.jpeg?mode=stretch&width=329&height=185&bgcolor=fff",
            "https://www.gsk.com/media/9932/vaccine-manufacturing-production-line-1.jpg?mode=stretch&width=329&height=185&bgcolor=fff",
            "https://www.gsk.com/media/10155/up_10_2022_lab_023_hess_jpg.png?mode=stretch&width=329&height=185&bgcolor=fff",
            "https://www.gsk.com/media/9354/trust_nicola_nav.jpg?mode=stretch&width=329&height=185&bgcolor=fff",
            "https://www.gsk.com/media/9346/web16-header-stvg_2_2022_port_13_hess_nav.jpg?mode=stretch&width=329&height=185&bgcolor=fff",
            "https://www.gsk.com/assets/img/back-to-to-arrow.svg"
        ],
        "movies": [],
        "keywords": [],
        "meta_keywords": [
            ""
        ],
        "tags": null,
        "authors": [],
        "publish_date": "2024-07-19T06:08:23",
        "summary": "",
        "meta_description": "Keep up to date with our latest new announcements",
        "meta_lang": "en",
        "meta_favicon": "/assets/img/favicons/favicon-96x96.png?v=1507259224",
        "meta_site_name": "",
        "canonical_link": "https://www.gsk.com/en-gb/media/press-releases/",
        "text": "15 July 2024\n\nViiV Healthcare to announce data from largest head-to-head randomised clinical trial for 2-drug regimen Dovato against 3-drug regimen Biktarvy at AIDS 2024\n\nThe presentation is one of 25 abstracts evaluating the company’s portfolio of marketed HIV treatment and prevention options.\n\n05 July 2024\n\nBrazil and Thailand become first malaria-endemic countries to launch new single-dose radical cure medicine to prevent the relapse of Plasmodium vivax malaria\n\nLaunch of single-dose tafenoquine, co-administered with chloroquine, is another step closer to global elimination of malaria.\n\n03 July 2024\n\nGSK and CureVac to restructure collaboration into new licensing agreement\n\nGSK acquires full rights to develop, manufacture and commercialise globally mRNA candidate vaccines for influenza and COVID-19.\n\n28 June 2024\n\nStatement: Zantac (ranitidine) litigation – Gross case\n\nGSK has reached a confidential settlement with Martin Gross resolving the case he filed\n\n26 June 2024\n\nStatement: US Centers for Disease Control and Prevention’s Advisory Committee on Immunisation Practices updates recommendations on adult RSV vaccines ahead of the next season\n\nGSK today announced that the US CDC ACIP voted in favour of recommending the routine use of RSV vaccines in all adults aged 75 and above.\n\n24 June 2024\n\nJemperli (dostarlimab) plus chemotherapy application accepted for review by the European Medicines Agency to expand use to all patients with primary advanced or recurrent endometrial cancer\n\nRegulatory submission supported by statistically significant and clinically meaningful progression-free and overall survival data\n\n24 June 2024\n\nGSK’s Omjjara (momelotinib) approved in Japan for treatment of myelofibrosis\n\nOmjjara approved for use in both newly diagnosed or previously treated myelofibrosis patients.\n\n10 June 2024\n\nStatement: Zantac (ranitidine) litigation – GSK starts process for appeal of recent Delaware Daubert decision\n\nGSK confirms that the Company has taken the first step to seek appeal of the recent Daubert ruling, made by the Delaware Superior Court.\n\n07 June 2024\n\nUS FDA approves expanded age indication for GSK’s Arexvy, the first respiratory syncytial virus (RSV) vaccine for adults aged 50-59 at increased risk\n\nOver 13 million US adults aged 50-59 years have a medical condition that increases their risk of severe RSV outcomes.\n\n06 June 2024\n\nGSK accelerates oligonucleotide platform and pipeline medicines with acquisition of Elsie Biotechnologies\n\nOligonucleotides are a unique modality with potential to address hard-to-treat diseases with high unmet need\n\n01 June 2024\n\nStatement: Zantac (ranitidine) litigation – Delaware State Court Daubert Ruling\n\nGSK disagrees with ruling by the Delaware State Court and will immediately seek an appeal.\n\n23 May 2024\n\nStatement: Zantac (ranitidine) litigation - Valadez and Williams cases\n\nJury in Valadez case in Illinois state court finds GSK not liable for plaintiff’s colorectal cancer\n\n23 May 2024\n\nNew data at ASCO showcases the transformational potential of GSK's oncology portfolio\n\nPivotal data will be shared from the DREAMM-8 and DREAMM-7 phase III trials.\n\n21 May 2024\n\nGSK announces positive results from phase III severe asthma trials of depemokimab\n\nPrimary endpoints met in SWIFT-1 and SWIFT-2 trials with statistically significant reduction in exacerbations over 52 weeks vs. placebo"
    }
}